Abstract
BackgroundClinical studies of intraperitoneal chemotherapy with paclitaxel in patients of gastric cancer with peritoneal carcinomatosis is well tolerated and effective, and rare cases of metastasis and recurrence have experienced during the treatment. Disseminated carcinomatosis of the bone marrow is highly rare in gastric cancer and associated with a poor prognosis.Case presentationA 59-year-old woman of gastric cancer with peritoneal carcinomatosis received five courses of chemotherapy with intraperitoneal administration of paclitaxel, and laparoscopy showed disappearance of the peritoneal carcinomatosis. She subsequently underwent total gastrectomy, and the histopathological findings showed a complete response to the chemotherapy. Postoperatively, chemotherapy with intraperitoneal administration of paclitaxel was continued for 30 months, without apparent recurrence. However, the gastric cancer recurred as disseminated carcinomatosis of the bone marrow with disseminated intravascular coagulation, and we hence changed the chemotherapy regimen to weekly irinotecan. Remission was achieved, and she did not experience any major symptoms; however, she died 6 months after the diagnosis of disseminated carcinomatosis of the bone marrow.ConclusionsSince intraperitoneal paclitaxel administration can strongly suppress peritoneal carcinomatosis of gastric cancer, careful attention should be paid not only to peritoneal recurrence but also for rare site metastases, such as bone marrow metastases.
Highlights
Clinical studies of intraperitoneal chemotherapy with paclitaxel in patients of gastric cancer with peritoneal carcinomatosis is well tolerated and effective, and rare cases of metastasis and recurrence have experienced during the treatment
Clinical studies investigating the effects of intraperitoneal chemotherapy with paclitaxel (PTX) performed by our group on such patients have shown that the treatment is well tolerated and effective [1,2,3]
Case presentation A 59-year-old woman was referred to our department for intraperitoneal chemotherapy for gastric cancer with peritoneal carcinomatosis
Summary
We here experienced a patient of gastric cancer with peritoneal carcinomatosis who developed DCBM 3 years after initiation of intraperitoneal chemotherapy with PTX. Since intraperitoneal PTX administration can strongly suppress peritoneal carcinomatosis of gastric cancer, careful attention should be paid to peritoneal recurrence and for rare site metastases, such as bone marrow metastases, during the course of intraperitoneal chemotherapy. HY contributed to the drafting of the work and surgery. JK and HI contributed to the revision of the work and surgery. TW gave final approval and took overall responsibility for the published work.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
